Let's not call it cancer at HealthBulance.

Researchers are developing tools for predicting how fast prostate cancer might progress; among the most promising are those that count circulating tumor cells (CTCs) in blood samples. Research shows that high CTC counts predict poorer survival and faster disease progression. But they are also predictive for early-stage metastatic prostate cancer that still responds to hormonal therapy. 2025-01-03

Radiation therapy for prostate cancer used to involve weeks or months of treatment. Today, radiation delivery is moving toward higher doses given with fewer sessions over shorter durations. Results from a clinical trial show that the two types of therapy offer the same long-term benefits. 2024-12-10

Radiation therapy for prostate cancer used to involve weeks or months of repeat visits to a clinic for treatment. Today, radiation delivery is moving toward higher doses given with fewer sessions over shorter durations. Results from a clinical trial show that the two types of therapy offer the same long-term benefits. 2024-12-05

Abnormal results on a prostate-specific antigen (PSA) screening test for cancer are typically followed by a systematic biopsy. But systematic biopsies can be problematic, and researchers are seeking alternatives. A large European study provides encouraging evidence favoring a different approach that uses MRI instead of biopsy. 2024-11-08

The specialized cells of our immune systems help to keep us healthy and free of infectious diseases. Immunotherapies teach those same cells to recognize and destroy cancer. Researchers are reporting promising results with a different method that involves engineered cells studded with receptors that bind to specific targets on cancer cells. 2024-09-16